Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
The International Journal on Drug Policy|February 6, 2026
Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic reviewThomas Santo, Matthew Hickman, Frederick L Altice, et al.
The International Journal on Drug Policy|February 6, 2026
The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic reviewLouisa Degenhardt, Matthew Hickman, Frederick L Altice, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 10, 2017
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infectionChaturaka Rodrigo, Melanie R Walker, Preston Leung, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
The International Journal on Drug Policy|January 6, 2026
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysisEvan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|April 18, 2022
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antiviralsAnita Y M Howe, Chaturaka Rodrigo, Evan B Cunningham, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
Nordisk Alkohol- & Narkotikatidskrift : NAT|April 7, 2025
A clarion call to the addiction science community: It's time to resist the anti-scientific policies of the US Trump administrationThomas F Babor, Bryon Adinoff, Luke Clark, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
The International Journal on Drug Policy|February 6, 2026
Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic reviewThomas Santo, Matthew Hickman, Frederick L Altice, et al.
The International Journal on Drug Policy|February 6, 2026
The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic reviewLouisa Degenhardt, Matthew Hickman, Frederick L Altice, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 10, 2017
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infectionChaturaka Rodrigo, Melanie R Walker, Preston Leung, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
The International Journal on Drug Policy|January 6, 2026
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysisEvan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|April 18, 2022
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antiviralsAnita Y M Howe, Chaturaka Rodrigo, Evan B Cunningham, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
Nordisk Alkohol- & Narkotikatidskrift : NAT|April 7, 2025
A clarion call to the addiction science community: It's time to resist the anti-scientific policies of the US Trump administrationThomas F Babor, Bryon Adinoff, Luke Clark, et al.
Pageof 37